- Oxford BioDynamics said it had signed a collaboration agreement with Italian research institution Casa Sollievo della Sofferenza to identify biomarkers for the blood-based diagnosis of autism spectrum disorder.

The agreement would see the groups use Oxford BioDynamics' EpiSwitch bio-market technology platform on blood samples from both autistic subjects and healthy controls provided by Casa Sollievo della Sofferenza.

Currently, diagnosis for autism remains challenging due to broad ranging symptoms and differential progression and manifestation of the disorder, the company said.

'As the EpiSwitch platform monitors the environmental impact on the genome, it is well placed to identify biomarkers for diagnosing ASD through minimally invasive blood sampling,' it added.

At 9:28am: [LON:OBD] Oxford Biodynamics Plc share price was -1p at 208p

Story provided by